Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IntriNSiC: L19IL2/L19TNF in Skin Cancers
NCT05329792Phase 2Recruiting
- Sponsor
- Philogen
- Start
- Mar 2023
- Primary completion
- Jun 2024
- Modality
- Antibody Fragments, Immunomodulatory ADCs, Cytokines & Interferons
- Countries
- 3
01
Overview
A Phase 2 trial of darleukin, onfekafusp alfa in basal cell carcinoma (BCC), squamous cell carcinoma (SCC), Merkel cell carcinoma (MCC), keratoacanthoma (KA), Malignant adnexal tumors of the skin (MATS), sponsored by Philogen. Started Mar 2023; status: recruiting.
02
Drugs
darleukinonfekafusp alfa
03
Conditions
basal cell carcinoma (BCC)squamous cell carcinoma (SCC)Merkel cell carcinoma (MCC)keratoacanthoma (KA)Malignant adnexal tumors of the skin (MATS)
Beyond the preview
Go deeper on NCT05329792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05329792.